Life sciences research centre
Avantor Performance Materials has opened a new life sciences research centre in Bridgewater, US.
The centre will provide contract research capabilities, including gene synthesis, protein expression, final formulation, and drug delivery.
The innovation centre employs research specialists including chemists and innovation associates to collaborate with biopharmaceutical and pharmaceutical companies to address their drug manufacturing processing objectives.
The facility was leased in June by Avantor from The Garibaldi Group/CORFAC International, a provider of real estate services based in the US.
Incorporating multiple pharmaceutical research platforms, the new centre will serve as a rapid response research hub for biopharmaceutical, biologic, and small molecule markets. It is expected to strengthen the company’s innovation capabilities in the pharmaceutical and life-sciences sector, as well as other advanced technologies.
The Bridgewater Innovation Center has a floor area of 26,769ft² and houses a variety of tools required to help pharmaceutical companies with a range of upstream and downstream bioprocesses in the fields of biopharma, analytical science, drug formulation, and drug delivery.
Pharmaceutical research tools available include multiple mass spectrometers, cleanroom facilities, particle size analysers, and specially constructed bioreactors.
The biopharmaceutical focus areas include facilitation of recombinant protein engineering, mid-scale bioreactor production, protein purification process development, protein expression, custom chromatography resins, host organism expression, and biophysical characterisation.
For analytical science applications, the facility will perform characterisation and quantitation of products, spectroscopic data for structure elucidation, microbial and endotoxin tests, profiling of organic impurities and elemental impurities down to 0.5 parts per billion (ppb), surface and particle characterisation and identification, and chromatographic characterisation of organic impurities.
Drug formulation and delivery activities at Avantor’s innovation centre consist of compatibility assessment of active pharmaceutical ingredients (API) or advanced current good manufacturing practice (cGMP) materials, a selection of excipients, control drug release profiles, loading of API in the drug formulation, and prototyping of drug device combinations.
Avantor’s new life-sciences research centre is located within the JR1 building of the New Jersey Center of Excellence life-sciences campus, which is situated on an 110-acre site in Bridgewater Township, New Jersey.
Situated on the US Highway 202/206 in the middle of the Boston-Washington wealth corridor, the site is well connected to major transportation routes. It is surrounded by approximately 3,000 life-sciences companies and is located close to top universities.
The research and development (R&D) campus was launched in April 2013 and is owned and managed by Advance Realty and investment firm CrossHarbor Capital Partners.
Headquartered in Pennsylvania, Avantor Performance Materials is engaged in supplying ultra-high-purity materials and solutions. It was originally founded as J.T.Baker Chemical Company in 1904 and serves roughly 7,900 customers globally with more than 30,000 products.
The company’s solutions are used for the research and production needs across various industries including pharmaceutical, bio materials, medical device, diagnostics, biotechnology, semiconductor, and aerospace.
Avantor’s products are marketed under brands including J.T.Baker®, Puritan Products™, Rankem™, BeneSphera™, POCH™, Macron Fine Chemicals™, CareSil, and NuSil™.
The Columbus Innovation District is a proposed healthcare and technology hub within the Ohio State University in the state of…
Lonza announced the expansion of its bioconjugation facility at its Visp site in Switzerland in December 2020. The expansion will…
Thermo Fisher Scientific (Thermo Fisher) will establish a new pharmaceutical services facility for integrated biologics and sterile drug development and…
Lykan Bioscience opened a purpose-built SMART Manufacturing™ facility for developing cell-based therapies in Hopkinton, Massachusetts, US, in September 2020. The…